Company / Depreciation & Amortization
IOVANCE BIOTHERAPEUTICS, INC. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$12.9M
FY2025
5-year range
$3.1M / $12.9M
FY2021-FY2025
Trend
+14.3%
vs FY2024
Sector context
#56 of 163
Health Care
What the data says
At $13M, IOVANCE BIOTHERAPEUTICS, INC.'s depreciation & amortization ranks #108 of 163 in the Health Care sector. Depreciation & Amortization has fluctuated over the past 10 years, ranging from $88,000 in FY2016 to $13M in FY2025.
Based on SEC 10-K filings.
$13M in FY2025 with a 5-year CAGR of +62.4%.
Increased from $12M to $13M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +11.4%
- 5-Year CAGR
- +62.4%
- 10-Year CAGR
- -
Sector benchmark
#108 of 163 in Health CareTop 66% of 163This company $12.9M Sector average $219.4M
▼
-94.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +62.4%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 14.3% year-over-year.
- Ranks #56 out of 163 companies in the Health Care sector.
- Lowest depreciation & amortization in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.9M | +14.3% |
| FY2024 | $11.3M | -2.7% |
| FY2023 | $11.6M | +24.3% |
| FY2022 | $9.3M | +199.3% |
| FY2021 | $3.1M | +172.9% |
| FY2020 | $1.1M | -2.5% |
| FY2019 | $1.2M | +22.3% |
| FY2018 | $956.0K | +0.4% |
| FY2017 | $952.0K | +981.8% |
| FY2016 | $88.0K | +1157.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026